Company Overview and News

140
It's Electric: Key Growth Investing Trends To Watch

23h seekingalpha
Electric vehicles have a long road ahead of them, even if Tesla sees a few twists and turns along the way.
PILBF SSNLF CCZ RNSDF HAV GALXF ALTAF GM.WS.A GM.WS.B GM.WS.C GM VLKAY PLS AYR BC94 SMSN BSWQY DDAIF TWNAF KATFF GXY KAT TAW GOOGL MU GM.WSB AJM SMSD

6
Tawana and Alliance a step closer to $446m merger

2018-06-12 australianmining.com.au
Tawana Resources’ proposed merger with Alliance Mineral Mineral Assets, first announced in April, has been given the go ahead by the Australian Government.
SPXCY TAW SPXCF EGS EGDD TWNAF 0024 ESGFF S68

0
Small and Mid-cap round up – 2018/06/07 | Decusatio

2018-06-07 decusatio.co.za
Markets are taking a chance to settle down after a rocky week last week. Sentiment continues to be cautious. These are some of the small and mid-cap stories from Wednesday on the JSE:
KIBO TAW TWNAF

2
Tawana strengthens Bald Hill mine life

2018-06-06 australianmining.com.au
Tawana Resources and Alliance Mineral Assets, the joint venture owners of the Bald Hill mine, have boosted the reserve at the Western Australian lithium-tantalum operation.
40F TAW TWNAF

8
Lithium anticipation rises to another level

2018-05-23 australianmining.com.au
Australia’s lithium sector was tipped to see a surge in mergers and acquisitions (M&A) and operational development this year — and so far it hasn’t disappointed.
PLS KDR PILBF MALRY TWNAF MIN 40F GXY GALXF TAW ALTAF MALRF AJM

1
Woomera Mining granted Western Australian ground prospective for lithium

2018-05-09 proactiveinvestors.com.au
Woomera Mining Ltd (ASX:WML) has been granted two new tenements prospective for hard-rock lithium in Western Australia.
GXY GALXF TAW ARK TWNAF

1
Woomera Mining granted Western Australian ground prospective for lithium

2018-05-03 proactiveinvestors.com.au
Woomera Mining Ltd (ASX:WML) has been granted two new tenements prospective for hard-rock lithium in Western Australia.
GXY GALXF TAW ARK TWNAF

2
Tawana Resources ships first batch of Bald Hill lithium concentrate to China

2018-05-03 proactiveinvestors.com.au
Tawana Resources NL (TAW:ASX) and Alliance Mineral Assets (SGX:40F) have shipped the first batch of spodumene (lithium) concentrate from the Bald Hill lithium and tantalum mine.
40F TAW TWNAF

3
Exports from Bald Hill lithium mine on track

2018-04-24 australianmining.com.au
Shipments of spodumene concentrate from the Bald Hill lithium-tantalum mine in Western Australia are set to start in early May.
40F TAW EGS EGDD TWNAF ESGFF

0
Tawana merges with Bald Hill partner

2018-04-05 businessnews.com.au
Lithium producer Tawana Resources has announced plans to merge with its Bald Hill project joint venture partner, Singapore-listed Alliance Minerals Assets, to form a $446 million company.
TAW TWNAF

8
Tawana to merge with Bald Hill lithium partner Alliance

2018-04-05 australianmining.com.au
Bald Hill lithium mine joint venture partners Tawana Resources and Alliance Mineral Assets are planning a merger to consolidate ownership of the Western Australian operation.
40F SPXCY TAW SPXCF EGS EGDD TWNAF ESGFF S68

3
Tawana completes successful first test at Bald Hill lithium plant

2018-03-29 australianmining.com.au
Tawana Resources and joint venture partner Alliance Mineral Assets have completed the first of three performance tests at the Bald Hill lithium plant in the Eastern Goldfields region of Western Australia, returning high-quality concentrate results in excess of 6 per cent lithium oxide.
40F TAW EGS EGDD TWNAF ESGFF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:TAW / TAWANA RESOURCES NL on message board site Silicon Investor.

Cartaway resources UDW - US Dataworks, Inc. Turnaround Play Under $1.00
DWCH-Datawatch Worth Watching! AWA Astaware Technologies (was ITM)
Metawave Communications Corporation (MTWV) HAND - Castaway Child of Mr.u0026 Mrs. Palm
DataWave Vending Inc. DWLD DataWorld
Dataware Technology (DWTI) Gud Subject Gud tawk